The active ingredient in Ozempic was associated with a reduced risk of Alzheimer's disease-related dementia among diabetes patients.

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

Three studies presented today at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether ...

A new review of clinical trial data finds evidence that GLP-1 drugs can meaningfully reduce dementia risk in people with type 2 diabetes.

Obesity and diabetes drugs, particularly semaglutides like Wegovy and Ozempic, may reduce a person’s risk of dementia, a new study suggests.

“According to the latest figures released by the NHS, dementia diagnosis is at a record high in England. “This is great news for residents, as increased awareness results in increased ...

Ozempic and similar novel diabetes treatments may lower the risk of Alzheimer's disease and related dementias. This is the conclusion of a pair of studies by research teams from the U.S. and ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk and potential applications for addiction treatment.

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.